JPRN-UMIN000037891
Completed
未知
A Prospective Epidemiology Study to Estimate the Attack Rate of Respiratory Syncytial Virus Infection in Adults Aged 65 Years and Older in Japan - A Prospective Epidemiology Study to Estimate the Attack Rate of Respiratory Syncytial Virus Infection in Adults Aged 65 Years and Older in Japan
Janssen Pharmaceutical K.K. R&D Clinical Science div. Infectious disease & Vaccine Clinical Development Dept.0 sites1,000 target enrollmentSeptember 2, 2019
ConditionsRespiratory Syncytial Virus Infections
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Respiratory Syncytial Virus Infections
- Sponsor
- Janssen Pharmaceutical K.K. R&D Clinical Science div. Infectious disease & Vaccine Clinical Development Dept.
- Enrollment
- 1000
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Respiratory syncytial virus was reported as a major pathogen for respiratory infection and represents a significant burden in the Japanese elderly population.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •\-Participants received any experimental antiviral drugs or vaccines against respiratory syncytial virus (RSV) within 6 months prior to the signing Informed Consent Form (ICFs) \- Participants who have acute respiratory disease (ARD) at the time of ICF and Week 0 (Baseline) at the discretion of the investigator \- Participants with life expectancy less than 1 year \- Participants unwilling to undergo nasopharyngeal swab procedures or with any physical abnormality which limits the ability to collect regular nasopharyngeal specimens \- Participant who is not able to comply with study\-related procedures,due to their mental status or severe clinical condition, based on clinical judgement of the investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Respiratory Syncytial Virus Infection in Exacerbations of Chronic Obstructive Pulmonary Diasease: the RECODE StudyRespiratory Synctial VirusCOPDChronic Obstructive Pulmonary Disease (COPD)Exacerbation of COPDNCT06735612Fundacio Privada Mon Clinic Barcelona892
Recruiting
Phase 2
RSV Vaccination in Immunocompromised Patients.RSV InfectionNCT06597916Medical University of Vienna200
Recruiting
Phase 3
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized InfantsNCT06775405Shanghai Ark Biopharmaceutical Co., Ltd.180
Completed
Early Phase 1
A Study of Acute Respiratory Infections in Global Outpatient SettingAcute Respiratory InfectionNCT05148780Janssen Research & Development, LLC245
Active, not recruiting
Phase 4
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsRespiratory Syncytial Virus InfectionNCT06551506National Institute of Allergy and Infectious Diseases (NIAID)181